Neeta Pradhan, MSc

CRS:

BJMC

Role:

Laboratory

Position:

TB Laboratory Coordinator

Email:

neetapradhanpune@gmail.com

Neeta Pradhan is TB Laboratory Coordinator at the BJGMC-CRS in Pune, India. She has worked as Laboratory Manager at Golwilkar Metropolis Health Services where she was responsible for technical and quality aspects of laboratory testing.

She worked as a Laboratory Coordinator at NARI (National AIDS Research Institute) Clinical Trial Unit for various NIH-funded clinical stuies in the HIV Prevention Trials Network (HPTN), the AIDS Clinical Trial Group (ACTG), and the Microbicide Trial Network (MTN). She was responsible for lab quality management, administration, monitoring and supervision, and coordination and communication as well as additional institutional responsibilities such as lab accreditation.

She has also handled CONDRAD (ICMR) project in the capacity of a Laboratory Coordinator at NARI. She is a NABL (National Accreditation Board for Testing & Calibration of laboratory) 15189 trained internal auditor as well as being trained at GCLP by PPD.

She completed her post graduation at BJGMC, which is affiliated with the University of Pune.

  • Voting Member, Laboratory Technologist Committee (Dec 2017-Nov 2019)
  • Member, TB Laboratory Core Team

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More